KayoThera specializes in pioneering a novel class of safe oral antagonists that are the first of their kind to target retinoid signaling. Previously considered “undruggable,” the retinoid pathway has posed challenges to drug development for nearly three decades. Past clinical experience with retinoid pathway activators has revealed two consistent findings among thousands of patients: adverse outcomes in solid cancers and a range of cardiometabolic effects, from hyperlipidemias to insulin resistance.

In response, KayoThera has developed a comprehensive pipeline of drugs focused on inhibiting retinoid signaling based on new biological insights to the pathway. The lead program in oncology aims to target retinoid synthesis in immune cells, while the cardiometabolic program concentrates on inhibiting retinoids in the pancreas, muscle, and fat-storing tissues. By pursuing this innovative approach, KayoThera aims to address critical medical needs and potentially revolutionize the treatment landscape in both oncology and cardiometabolic diseases.